Cargando…

Profiles of prognostic alternative splicing signature in hepatocellular carcinoma

Previous studies have demonstrated the role of abnormal alternative splicing (AS) in tumor progression. This study examines the prognostic index (PI) of alternative splices (ASs) in patients with hepatocellular carcinoma (HCC). The clinical features and splicing events of patients with HCC were down...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Fangming, Chen, Qifeng, Liu, Chaojun, Duan, Xiaoran, Hu, Jinlong, Liu, Jian, Cao, Huicun, Li, Wang, Li, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064038/
https://www.ncbi.nlm.nih.gov/pubmed/31975560
http://dx.doi.org/10.1002/cam4.2875
_version_ 1783504804618698752
author Wu, Fangming
Chen, Qifeng
Liu, Chaojun
Duan, Xiaoran
Hu, Jinlong
Liu, Jian
Cao, Huicun
Li, Wang
Li, Hui
author_facet Wu, Fangming
Chen, Qifeng
Liu, Chaojun
Duan, Xiaoran
Hu, Jinlong
Liu, Jian
Cao, Huicun
Li, Wang
Li, Hui
author_sort Wu, Fangming
collection PubMed
description Previous studies have demonstrated the role of abnormal alternative splicing (AS) in tumor progression. This study examines the prognostic index (PI) of alternative splices (ASs) in patients with hepatocellular carcinoma (HCC). The clinical features and splicing events of patients with HCC were downloaded from The Cancer Genome Atlas (TCGA). Differentially expressed AS (DEAS) were compared between HCC and adjacent normal samples. Univariate Cox regression analysis was used to determine changes in DEAS associated with overall survival (OS). A PI was generated from OS‐associated DEASs using Kaplan‐Meier curves, receiver operating characteristic (ROC) curves, multivariate Cox regression, and cluster analysis. Then, the correlation between DEASs and splicing factors was assessed, followed by functional and pathway enrichment analysis. We identified 34 163 ASs of 8985 genes in HCC, and 153 OS‐ASs were identified using univariate Cox regression analysis. Low‐ and high‐PI groups were determined based on the median “PI‐ALL” value according to significantly different survival (P = 2.2e − 16). The ROC curve of all PI (PI‐ALL) had an area under the curve (AUC) of 0.993 for survival status in patients with HCC. A potential regulatory network associated with prognosis of patients with HCC was established. Enrichment analysis also resulted in the identification of several pathways potentially associated with carcinogenesis and progression of HCC. Four clusters were identified that were associated with clinical features and prognosis. Our study generated comprehensive profiles of ASs in HCC. The interaction network and functional connections were used to elucidate the underlying mechanisms of AS in HCC.
format Online
Article
Text
id pubmed-7064038
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-70640382020-03-16 Profiles of prognostic alternative splicing signature in hepatocellular carcinoma Wu, Fangming Chen, Qifeng Liu, Chaojun Duan, Xiaoran Hu, Jinlong Liu, Jian Cao, Huicun Li, Wang Li, Hui Cancer Med Cancer Biology Previous studies have demonstrated the role of abnormal alternative splicing (AS) in tumor progression. This study examines the prognostic index (PI) of alternative splices (ASs) in patients with hepatocellular carcinoma (HCC). The clinical features and splicing events of patients with HCC were downloaded from The Cancer Genome Atlas (TCGA). Differentially expressed AS (DEAS) were compared between HCC and adjacent normal samples. Univariate Cox regression analysis was used to determine changes in DEAS associated with overall survival (OS). A PI was generated from OS‐associated DEASs using Kaplan‐Meier curves, receiver operating characteristic (ROC) curves, multivariate Cox regression, and cluster analysis. Then, the correlation between DEASs and splicing factors was assessed, followed by functional and pathway enrichment analysis. We identified 34 163 ASs of 8985 genes in HCC, and 153 OS‐ASs were identified using univariate Cox regression analysis. Low‐ and high‐PI groups were determined based on the median “PI‐ALL” value according to significantly different survival (P = 2.2e − 16). The ROC curve of all PI (PI‐ALL) had an area under the curve (AUC) of 0.993 for survival status in patients with HCC. A potential regulatory network associated with prognosis of patients with HCC was established. Enrichment analysis also resulted in the identification of several pathways potentially associated with carcinogenesis and progression of HCC. Four clusters were identified that were associated with clinical features and prognosis. Our study generated comprehensive profiles of ASs in HCC. The interaction network and functional connections were used to elucidate the underlying mechanisms of AS in HCC. John Wiley and Sons Inc. 2020-01-24 /pmc/articles/PMC7064038/ /pubmed/31975560 http://dx.doi.org/10.1002/cam4.2875 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cancer Biology
Wu, Fangming
Chen, Qifeng
Liu, Chaojun
Duan, Xiaoran
Hu, Jinlong
Liu, Jian
Cao, Huicun
Li, Wang
Li, Hui
Profiles of prognostic alternative splicing signature in hepatocellular carcinoma
title Profiles of prognostic alternative splicing signature in hepatocellular carcinoma
title_full Profiles of prognostic alternative splicing signature in hepatocellular carcinoma
title_fullStr Profiles of prognostic alternative splicing signature in hepatocellular carcinoma
title_full_unstemmed Profiles of prognostic alternative splicing signature in hepatocellular carcinoma
title_short Profiles of prognostic alternative splicing signature in hepatocellular carcinoma
title_sort profiles of prognostic alternative splicing signature in hepatocellular carcinoma
topic Cancer Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064038/
https://www.ncbi.nlm.nih.gov/pubmed/31975560
http://dx.doi.org/10.1002/cam4.2875
work_keys_str_mv AT wufangming profilesofprognosticalternativesplicingsignatureinhepatocellularcarcinoma
AT chenqifeng profilesofprognosticalternativesplicingsignatureinhepatocellularcarcinoma
AT liuchaojun profilesofprognosticalternativesplicingsignatureinhepatocellularcarcinoma
AT duanxiaoran profilesofprognosticalternativesplicingsignatureinhepatocellularcarcinoma
AT hujinlong profilesofprognosticalternativesplicingsignatureinhepatocellularcarcinoma
AT liujian profilesofprognosticalternativesplicingsignatureinhepatocellularcarcinoma
AT caohuicun profilesofprognosticalternativesplicingsignatureinhepatocellularcarcinoma
AT liwang profilesofprognosticalternativesplicingsignatureinhepatocellularcarcinoma
AT lihui profilesofprognosticalternativesplicingsignatureinhepatocellularcarcinoma